Wen Xie

11PUBLICATIONS
57CO-AUTHORS
Molecular targetsMedical devicesProteomics and intermolecular interactions (excl. medical proteomics)Epidemiological modellingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 09, 2026
CRISPR activation screens identify oncogenic lncRNAs that are susceptible to CDK4/6 inhibitor treatment.

Yifei Wang, Yueshan Zhao, Jiaxin Hu

|Jan 19, 2026
Targeting ADAR1-mediated RNA editing inhibits hepatic stellate cell activation and liver fibrosis by enhancing HSC-intrinsic innate immunity.

Yue Xi, Lingyi Liu, Jong-Won Kim

|Oct 23, 2025
Redox regulation by sulfiredoxin-1: bridging cysteine oxidation and liver disease therapeutics.

Jong-Won Kim, Mengyun Ke, Donovan Whitfield

|Sep 29, 2025
A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation.

Pengfei Xu, Yue Xi, Jong-Won Kim

|Aug 12, 2025
The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition.

Dhamotharan Pattarayan, Yue Wang, Zehua Wang

|Sep 25, 2024
Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose.

Hung-Chun Tung, Jong-Won Kim, Junjie Zhu

Pageof 2

Frequent Collaborators

7 joint publications

Da Yang

4 joint publications

Pengfei Xu

4 joint publications

Song Li

3 joint publications

Yue Xi